[{"id":"4565cd60-700f-40d2-a4d5-801fe8a26059","acronym":"ModuLung","url":"https://clinicaltrials.gov/study/NCT02852083","created_at":"2021-01-18T13:59:56.649Z","updated_at":"2024-07-02T16:37:14.716Z","phase":"Phase 2","brief_title":"A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC","source_id_and_acronym":"NCT02852083 - ModuLung","lead_sponsor":"University Hospital Regensburg","biomarkers":" EGFR • ALK • PD-1 • RAS • PPARG • PPARA","pipe":"","alterations":" ","tags":["EGFR • ALK • PD-1 • RAS • PPARG • PPARA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Grafapex (treosulfan)"],"overall_status":"Unknown status","enrollment":" Enrollment 86","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 07/01/2019","primary_completion_date":" 07/01/2019","study_txt":" Completion: 07/01/2020","study_completion_date":" 07/01/2020","last_update_posted":"2018-01-18"}]